News

Press Release

2025

2024

2023

2022

2021

2020

2019

2018

2017

Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation